1.Knowledge, attitude, practice survey (KAP) on liver disease, hepatitis B and EPI at Thanh Hoa
Journal of Preventive Medicine 2001;11(2):18-23
The KAP survey on liver disease, hepatitis B and EPI was conducted in Quang Xuong and Ngoc Lac (Thanh Hoa) in October 2000. The results: there were more than 50% of interviewees giving completely correct answers on liver disease. Monthly visits of EPI staffs increased three times in Ngoc Lac to compare with this of 3 years ago. Radio/TV and loudspeakers are still the main ways to inform EPI activities. Knowledge of mothers on vaccination has been improved. The rate of having birth at CHS has increased in Ngoc Lac (from 6.2% to 34.2%)
Hepatitis, Chronic
;
hepatitis B
2.Antiviral therapy of chronic hepatitis B.
Korean Journal of Medicine 2002;62(6):687-689
No abstract available.
Hepatitis B, Chronic*
;
Hepatitis, Chronic*
3.Antiviral therapy for the management of chronic hepatitis B.
Korean Journal of Medicine 2004;67(3):224-230
No abstract available.
Hepatitis B, Chronic*
;
Hepatitis, Chronic*
4.Current Antiviral Therapy of Chronic Hepatitis B and C.
Journal of the Korean Medical Association 1999;42(9):898-906
No abstract available.
Hepatitis B, Chronic*
;
Hepatitis, Chronic*
6.Changes of the amount and rate of lymphocyte T in patients with acute or chronic hepatitis B and cirrhosis
Journal of Practical Medicine 2002;430(9):7-10
A study on 105 patients in the Institute of Clinical Medicine and Tropical Diseases from 12/1997-1/1999 has shown that the lymphocyte TCD 3, TCD4 and TCD8 increased in patients with acute hepatitis B, these cells remained at normal level in patients with the chronic hepatitis B, there was an increase of lymphocyte TCD4 in patients with cirrhosis. The amount of lymphocyte was significantly reduced. The lymphocyte T in the patients with acute hepatitis B was higher than these in patients with chronic hepatitis B.
Hepatitis B
;
Fibrosis
;
Hepatitis B, Chronic
8.Thymosin-a 1 for treatment of chronic hepatitis B
Journal of Medical and Pharmaceutical Information 2004;0(7):21-24
A study on 56 patients with chronic hepatitis B who were divided into 2 groups: study group and control group. The study group including 31 patients was treated with Thymosin-α1 1.6mg/day, twice a week for 6 months. The control group with 25 patients of same clinical data was treated with common liver-protective drugs. Both groups were monitored and assessed after 24 months. The results showed that the study group with treatment of Thymosin-α1 is better than control one in all aspects of ALT normalization, sero-conversion and decrease of HBV-DNA<5 copies/ml
Hepatitis B, Chronic
;
Therapeutics
10.Study of the effectiveness in treating chronic hepatitis B of Atcanninh in hospital 103
Journal Reasearch of Vietnam Traditional Medicine and Pharmacy 2005;15():18-23
Study on 60 patients with chronic hepatitis at Infectious diseases department, hospital 103 from February to July 2003. Patients were divided into 2 groups: group 1 included 30 patients who were treated by Atcanninh pack 20g, 3 packs/day; group 2 included 30 patients who were treated by glucose, bile tonic drug, Vitamin B, C. Results: Atcanninh could reduce rapidly some clinical symptoms as fatigue, lose appetite, jaundice, yellow urine. It reduced quickly the blood level of SGOT, SGPT and Bilirubin after 2 to 3 weeks of treatment. Comparing to control group, Atcanninh reduced significantly HBsAg, HBV-DNA concentrations and rate of seroconversion also higher (14.3% compares to 0% with p<0.05) after 3 months
Hepatitis B, Chronic
;
Therapeutics
Result Analysis
Print
Save
E-mail